This experimental medicine, mechanistic, multicentre, randomised, double-blind, placebo-controlled trial aims to evaluate the effect of belimumab combined with rituximab on time to PR3 ANCA antibody negativity in participants with PR3 ANCA associated vasculitis (see Additional file 1 for the SPIRIT 2013 Checklist). Here, PRTN3 is linked to vasculitis.